Fluoguide AS

Chart & Performance

D1W1MN

P/E

—

P/S

941.53

EPS

—

Div Yield, %

—

Shrs. gr., 5y

14.89%

Rev. gr., 5y

Revenues

385k

-8.98%

Net income

-29m

L-24.54%

CFO

-29m

L-8.35%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.

URL

https://fluoguide.com/

IPO date

May 07, 2019

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title DKK in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title DKK in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT